A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Axial Spondyloarthritis.

Trial Profile

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Axial Spondyloarthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Spondylarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ABILITY-1
  • Sponsors Abbott GmbH & Co. KG; AbbVie
  • Most Recent Events

    • 05 Apr 2017 Results of a post-hoc analysis assessing changes in objective inflammation over time in patients who had clinically active disease but a normal MRI (n=94), published in the Rheumatology
    • 30 Oct 2013 Post-hoc analysis in patients with elevated C-reactive protein or MRI evidence of inflammation presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 30 Oct 2013 Post-hoc analysis of MRI-positive/C-reactive protein-positive patients over 104 weeks presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top